Chevy Chase Trust Holdings LLC reduced its stake in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 2.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 90,157 shares of the medical research company’s stock after selling 2,172 shares during the quarter. Chevy Chase Trust Holdings LLC owned about 0.05% of IQVIA worth $14,208,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. Brighton Jones LLC increased its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of IQVIA by 56.3% during the first quarter. GAMMA Investing LLC now owns 2,197 shares of the medical research company’s stock valued at $387,000 after buying an additional 791 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock valued at $2,338,000 after buying an additional 3,398 shares during the last quarter. Sowell Financial Services LLC purchased a new position in shares of IQVIA during the first quarter valued at approximately $305,000. Finally, ORG Wealth Partners LLC purchased a new position in shares of IQVIA during the first quarter valued at approximately $60,000. 89.62% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
IQV has been the subject of a number of recent analyst reports. Barclays upped their price objective on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Thursday, October 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $195.00 to $225.00 in a research report on Tuesday, September 9th. Robert W. Baird upped their price target on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research report on Wednesday, July 23rd. Finally, Redburn Partners set a $214.00 price target on IQVIA in a research report on Wednesday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $234.57.
IQVIA Stock Performance
Shares of IQV opened at $204.51 on Friday. The stock’s 50-day simple moving average is $191.41 and its 200 day simple moving average is $169.19. The stock has a market capitalization of $34.77 billion, a price-to-earnings ratio of 29.60, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $237.21.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Insider Transactions at IQVIA
In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.
IQVIA Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More
- Five stocks we like better than IQVIA
- What Are Dividend Contenders? Investing in Dividend Contenders
- Johnson & Johnson’s M&A Strategy Is the Real Story for Investors
- What to Know About Investing in Penny Stocks
- Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?
- Using the MarketBeat Dividend Tax Calculator
- Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.